Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apremilast plus doxycycline in cutaneous pemphigoid
NL-OMON21799Recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of apremilast and doxycycline in pemphigoid, sponsored by University Medical Center Groningen. Primary endpoint: Partial remission. Started Jul 2019; status: recruiting.
02
Drugs
apremilastdoxycycline
03
Conditions
pemphigoid
Beyond the preview
Go deeper on NL-OMON21799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON21799.